A study identified several potential miRNAs as biomarkers for diffuse large B-cell lymphoma (DLBCL) prognoses. The findings were published in Bioscience Reports.
In this study, researchers used 12 patients with DLBCLs to screen out miRNA profiles using miRNA microarray technology in two patient subtypes: germinal center B-like (n=6), and non-germinal center (n=6). They further assessed potential biomarkers using the quantitative reverse transcription-polymerase chain reaction method in 95 patients with DLBCL in an effort to characterize the relationships between miRNA expression levels, clinicopathological features, and survival rates. The following miRNAs were screened as potential biomarkers: miR-208a-5p, miR-296-5p, and miR-1304-5p.
The results showed that miR-208a-5p and miR-296-5p were correlated with improved survival, whereas miR-1304-5p overexpression indicated a poor survival prognosis independent of the DLBCL subtype. Moreover, the researchers noted, changes of miR-296-5p and miR-1304-5p expression, the International Prognostic Index status, and the age of patients were all independent indicators for DLBCL prognosis.
“MiR-208a-5p, miR-296-5p and miR-1304-5p levels might be potential biomarkers for the prediction of the prognosis of DLBCL patients,” the researchers concluded.
Keywords: diffuse large B-cell lymphoma, miRNA, microarray, prognosis, qRT-PCR